A total of 1,501 distinct fusions in at least one of the nine driver genes assessed (ALK, RET, ROS1, NTRK1/2/3, FGFR2, FGFR3, and NRG1; Fig. 1) were detected in 1,497 patients (Table 1; Fig. 2) for a combined prevalence of 2.2% across the pan-cancer cohort. The gene discussed is FGFR2; the disease is cancer.